187 results about "Protein level" patented technology

The invention belongs to the field of antibodies, and particularly relates to a p-Tau217 phosphorylated protein binding antibody or an antigen binding part thereof and application thereof. The invention provides the amino acid sequences of the heavy chain CDR and the light chain CDR of the antibody specifically bound with the p-Tau217 phosphorylated protein, and the antibody can specifically recognize and bind the p-Tau217 phosphorylated protein and has the advantages of high affinity and good specificity to the protein. Based on the advantages, the antibody can be applied to diagnosis of diseases (such as nervous system degenerative diseases) related to abnormal p-Tau217 phosphorylated protein level, and especially can be applied to clinical diagnosis of Alzheimer's disease.

The invention provides an intelligent optimization method for carbon emission reduction of an ecological pasture in extreme weather, and relates to the technical field of intelligent optimization of carbon emission reduction. Comprising the steps that initial monitoring data are collected and preprocessed, and multi-dimensional feature vector output state features are constructed; an LSTM time sequence prediction model is used for analyzing the state of the dairy cow and the activity of methanogens in the rumen, DHI data of an integrated gradient boosting tree model is used for analyzing the amino acid balance and precise nutrition technology of the lactating dairy cow, a dairy cow manure yield prediction model based on a Bayesian network is constructed, a manure management strategy is dynamically optimized, and manure management effect data is output. And constructing a carbon emission reduction comprehensive evaluation model, and evaluating the pasture carbon emission reduction effect. According to the invention, the rumen flora structure is regulated and controlled, the rumen greenhouse gas emission is controlled, the ruminant feed protein level is reduced, and the methane emission is reduced by researching the dairy cow carbon emission rumen microorganism regulation and control technology.

To provide an estimation method for estimating the amount of marker proteins in the stratum corneum. [Solution] Identify one or more cell regions, stratified exfoliation regions, and single-cell regions in the stratum corneum image. A marker protein quantity estimation method that estimates the amount of marker proteins in the stratum corneum from stratum corneum images based on the correlation between the obtained stratum corneum parameters as explanatory variables and one of the following as the dependent variable: Enolase-1 quantity, FABP5 quantity, or Polyamine quantity.

The invention belongs to the technical field of biological medicine, and particularly provides application of flufenidone in preparation of a medicine for preventing or treating left heart failure. The research finds that the flufenidone has the effects of relieving myocardial cell hypertrophy under a heart failure cell model and relieving myocardial hypertrophy, fibrosis and heart function deterioration of an aortic constriction animal model. According to the present invention, further research results show that fluorofenidone is directly combined with SERCA2a through Q758, D812 and E917 residues of SERCA2a so as to inhibit recognition, combination and polyubiquitination effects of WWP1 on SERCA2a, such that the protein level and the activity of SERCA2a are stabilized so as to achieve the chronic left heart failure treatment purpose. Therefore, the flufenidone serving as an active ingredient has good application prospect and application value in research and development of novel medicines for treating chronic left heart failure.

The application relates to a compound medicine for delaying skeletal muscle aging and application thereof, and the medicinal active components in the compound medicine composition are composed of menadione bisulfite sodium and N-acetyl cysteine, and belong to the technical field of biological medicine. A novel drug combination mode is developed, an oxidant menadione bisulfite sodium (MBS) and an antioxidant N-acetyl-L-cysteine (NAC) are combined and given in different time periods to regulate the H2O2 circadian rhythm of the skeletal muscle of old mice, the changes of the muscle strength, histopathology and aging marker protein level of the skeletal muscle of the old mice are detected, and then the precise compound medicine capable of improving the skeletal muscle function of the old mice and delaying skeletal muscle aging is determined. The application provides an effective drug combination strategy for relieving or treating the delay of skeletal muscle aging, and has very significant meaning.

The application provides an arginine methyltransferase 6 inhibitor and a preparation method, a pharmaceutical composition and a use thereof, relates to the technical field of biological medicine. The arginine methyltransferase 6 inhibitor provided by the application is a new compound obtained on the basis of a large number of design, synthesis and screening. The arginine methyltransferase 6 inhibitor is different from existing PRMTs inhibitors. The arginine methyltransferase 6 inhibitor can selectively degrade arginine methyltransferase 6, thereby regulating the protein level of arginine methyltransferase 6, has antitumor cell activity, can be used for preventing or treating diseases related to abnormal expression of PRMT6, and provides a new choice for development and application of antitumor drugs. The preparation method of the arginine methyltransferase 6 inhibitor provided by the application adopts raw materials which are easy to obtain, has the advantages of simple synthesis method, safety, easy realization and high yield, and can be used for industrial production.

Provided herein are compounds and compositions thereof that reduce FAK protein levels. In some embodiments, the compounds have structures of Formula I:In some embodiments, the compounds and compositions are provided for treatment of FAK associated diseases such as cancer.

The invention discloses a 2-aminoquinazoline derivative as well as a preparation method and application thereof, and relates to the technical field of organic synthesis. The 2-aminoquinazoline derivative disclosed by the invention has a structure as shown in a formula I or a formula II. On the basis of a simple and efficient synthesis route, a plurality of 2-aminoquinazoline derivatives are rapidly constructed by using commercially available and low-cost raw materials and reagents through modular design; the 2-aminoquinazoline derivative has an obvious protective effect on cytopathy caused by viruses, shows down-regulation effect on virus RNA and protein level, lays a solid foundation for subsequent drug development and optimization, and has a wide application prospect.

The invention discloses application of C1INH in preparation of a product for prediction or auxiliary diagnosis of preeclampsia and the product, belongs to the technical field of biological medicines, and aims to detect the content of C1INH in a blood sample on a protein level by taking the blood sample of a subject as a detection object. According to the invention, C1INH molecules in blood are taken as a detection index, prediction and auxiliary diagnosis of preeclampsia of pregnant women can be realized, high sensitivity and specificity are realized, rapid detection can be realized, and a new way is provided for early screening and diagnosis of preeclampsia in the prior art.

The invention relates to the technical field of biological medicines, and particularly discloses siRNA for inhibiting CD44v6 expression in tumors and application of the siRNA. The siRNA molecule can specifically target mRNA of CD44v6, and efficient knock-down is achieved on the gene level and the protein level (the interference efficiency reaches 70%-90%); in-vitro experiments prove that the siRNA can significantly inhibit the proliferation ability and clone formation ability of gastric cancer cells (such as AGS and HGC-27); in-vivo and in-vitro experiments further show that the siRNA can enhance the sensitivity of gastric cancer cells to a ferroptosis inducer RSL3 and generate a synergistic anti-tumor effect. The invention further provides a pharmaceutical composition containing the siRNA and application of the pharmaceutical composition in preparation of drugs for treating malignant tumors such as gastric cancer, and a new strategy and means are provided for overcoming the problem that tumor progression is fast.

The invention relates to the technical field of biological medicines, and particularly discloses application of Creld2 as an early biomarker in diagnosis, prediction or prognosis of sepsis. By detecting the Creld2 protein level of the blood of a patient, early rapid diagnosis of sepsis is realized, or by detecting the Creld2 protein level of the blood of a sepsis patient, severity and 28-day survival condition of sepsis are evaluated. Compared with the prior art, the marker has the advantages that ROC curves for diagnosing sepsis and distinguishing severity of the sepsis are greater than 0.9, so that the Creld2 serving as the early marker of the sepsis has relatively high diagnosis efficiency and has the advantages of high sensitivity and high specificity.

The invention discloses an anti-DLL3 antibody as well as a preparation method, a drug conjugate and application thereof. The anti-DLL3 antibody disclosed by the invention has very good internalization activity, relatively good binding activity with human DLL3 protein and relatively strong affinity at the protein level; the DLL3-targeting antibody coupling drug has good druggability, biological activity and in-vivo and in-vitro anti-tumor activity, and application of cytotoxic drugs in treatment of tumor patients with neuroendocrine characteristics including SCLC can be realized by the DLL3-targeting antibody coupling drug.

The invention relates to a specifically degraded KIM1 liposome, preparation thereof and application of the specifically degraded KIM1 liposome in preparation of medicines for treating kidney diseases, and belongs to the technical field of biological medicines. According to the invention, a KIM1 targeting polypeptide and an E3 ubiquitin ligase ligand (such as lenalidomide) are respectively modified on the surface of a liposome. The lipidosome capable of specifically degrading the KIM1 can be rapidly enriched in a damaged kidney after renal injury occurs, and the KIM1 protein level in the damaged kidney is degraded by 75%. Meanwhile, the druggability problems of poor solubility, low bioavailability and the like caused by large molecular weight of the compound in the PROTAC drug development process are avoided, and the technical problems that drugs are difficult to prepare and kidney injury drugs are lacked in the prior art are solved.

The invention relates to the technical field of medicine, in particular to a brazilin-containing pharmaceutical composition and a preparation method and application thereof, and preparation raw materials comprise brazilin and a zinc preparation. Through the synergistic effect of the brazilin and the zinc preparation, the fibrosis area after myocardial infarction can be remarkably reduced, the cardiac function after myocardial infarction can be improved, and the cardiac fibrosis degree can be effectively relieved by inhibiting the expression of fibrosis-related genes and proteins at transcription and protein levels.

The application discloses application of an inhibitor targeting NLRP3 gene in promoting axon regeneration after sciatic nerve injury. It is found for the first time that NLRP3 expression in DRG is significantly up-regulated after sciatic nerve injury. Further, by interfering with the expression of NLRP3 through siRNA targeting NLRP3, the protein level of NLRP3 can be significantly inhibited, and the increase of the number of DRG neuron axons, the total length of axons and the longest axon length can be obviously promoted. The in-vitro and in-vivo experimental results show that NLRP3 is a negative regulation factor of axon regeneration after sciatic nerve injury, and targeted inhibition of NLRP3 expression can effectively promote axon regeneration. Based on this, the application provides an siRNA sequence targeting NLRP3 and application of the siRNA sequence in preparation of a drug for promoting axon regeneration after sciatic nerve injury. The application provides a new molecular target and intervention strategy for peripheral nerve injury repair, and has important theoretical research value and clinical application prospect.

The invention provides an oligopeptide targeting SUV39H1 and application of the oligopeptide in tumor treatment. The amino acid sequence of the oligopeptide is shown as SEQ ID NO: 1. According to the oligopeptide, a PRMT1 and SUV39H1 binding region is precisely targeted, so that the interaction between the PRMT1 and the SUV39H1 is effectively blocked, meanwhile, the methylation level and the protein level of the SUV39H1 are reduced, and precise targeted intervention on the SUV39H1 is realized. The invention provides a novel SUV39H1 intervention means which is accurate in targeting, high in safety and wide in application range, and the technical bottleneck of current tumor treatment is broken through.

The invention provides an oligopeptide, and a lentiviral expression vector and a recombinant cell for expressing the oligopeptide. The invention further provides application of the compound in tumor treatment. After the oligopeptide is delivered to HT1080 cells through a lentivirus system, the intracellular SLC7A11 protein level is reduced, the intracellular Fe < 2 + > and lipid peroxidation level is remarkably increased, and the oligopeptide has a remarkable inhibition effect on cell proliferation and has the tumor treatment potential.

The application discloses application of a killer cell lectin-like receptor G1 (KLRG1) gene as a marker in preparation of a systemic lupus erythematosus (SLE) secondary hemophagocytic lymphohistiocytosis (HLH) detection preparation, and the preparation is used for detecting the expression level of the KLRG1 gene in a biological sample. Research finds that the expression level of the KLRG1 gene in SLE secondary HLH patients is significantly lower than that of healthy control groups and SLE patients, and has good diagnostic sensitivity and specificity. The application also discloses a preparation for detecting the expression level of the KLRG1 gene in a biological sample of a patient, the preparation contains a primer pair for detecting the mRNA level of the KLRG1 gene expression, or contains an antibody for detecting the protein level of the KLRG1 gene expression, and only needs to extract peripheral blood mononuclear cells (PBMC) after blood drawing to detect whether SLE patients are secondary to HLH, and the preparation is simple, rapid, and accurate in result.

Aspects of the invention provide an AAV product that delivers an FXN gene supplementation or replacement strategy throughout the human CNS and heart at levels of DNA biodistribution, RNA expression, and FXN protein levels expected to restore function in Friedrich's ataxia patients.

A dsRNA agent for inhibiting angiotensinogen expression, a derivative thereof, and a use thereof. A corresponding dsRNA is designed for angiotensinogen (AGT), and is conjugated with Gal-NAc to effectively deliver the dsRNA to the liver, so as to interfere with AGT mRNA in the liver, thereby effectively reducing the synthesis and secretion of AGT. The provided dsRNA can significantly inhibit the expression of AGT mRNA in cells, effectively reduce AGT protein levels, has a long duration of action, and can be used for the preparation of a drug for treating hypertension.

The invention belongs to the technical field of biology, and particularly relates to an African swine fever virus P30 protein single-chain antibody and preparation and application thereof. The invention provides the single-chain antibody 7B9 aiming at the African swine fever virus P30 protein, the single-chain antibody can specifically react with the African swine fever virus P30 protein, and the single-chain antibody has the advantages of good sensitivity, strong antigen binding capacity, strong biological activity and the like; the single-chain antibody 7B9 is applied to establishment of an African swine fever virus blocking ELISA antibody detection method, and an effective detection method is provided for prevention and control of ASF; the single-chain antibody provided by the invention is recombined and modified by a gene engineering method, and is optimized on gene and protein levels, so that the long-term cryopreserved antibody loss of hybridoma cells is avoided, the specificity and affinity of the antibody are improved, and compared with the traditional monoclonal antibody, the scFv-7B9 antibody is lower in preparation cost and higher in specificity. The method is suitable for short-term and rapid large-scale fermentation preparation, and has high cost performance.

The invention provides an application method of a PPAR gamma agonist in preparation of a medicine for inhibiting ferroptosis of nucleus pulposus cells, and belongs to the technical field of medicine preparation.The PPAR gamma agonist pioglitazone and TAT cell-penetrating peptide are combined to form a compound, the compound is encapsulated in hyaluronic acid modified pH-sensitive lipidosome to construct a nucleus pulposus targeted drug delivery system, and the nucleus pulposus targeted drug delivery system is used for inhibiting ferroptosis of the nucleus pulposus cells. The flow cytometry is utilized to detect the physicochemical properties of the drug delivery system, the optimal drug delivery parameters are determined through a double-layer game optimization model, the drug release kinetics is determined in different pH environments to establish a pH response release model, and finally the PPAR gamma and Axl protein expression levels and the GPX4 protein level are detected through the fluorescence luminescence to verify the ferroptosis resisting effect. The technical problem that a drug carrier system cannot realize dual-function collaborative optimization of targeted delivery and acid-sensitive controlled release of nucleus pulposus cells is solved.

This application discloses a combination of plasma protein biomarkers for predicting healthy longevity and a screening method thereof, relating to the field of bioinformatics. The method includes: acquiring genetic association data between plasma proteins and the healthy longevity phenotype; extracting single nucleotide polymorphisms (SNPs) associated with plasma protein levels as instrumental variables; using Mendelian randomization to identify plasma proteins causally associated with the healthy longevity phenotype and performing sensitivity analysis; performing mediation analysis on the causally associated plasma proteins to identify plasma proteins that influence the healthy longevity phenotype through health-related factors; and constructing a combination of plasma protein biomarkers from the identified plasma proteins. This application screens proteins causally associated with healthy longevity and mediated by health-related factors from genetic association data to construct biomarker combinations, solving the technical problem of low prediction accuracy caused by prior art relying solely on correlation analysis, and achieving the technical effect of improving the prediction accuracy of biomarkers.

The invention discloses an application of PINK1 in regulation and control of ER positive breast cancer tamoxifen drug resistance. The invention relates to application of PINK1 as a biomarker in evaluating the tamoxifen resistance of ER positive breast cancer cells. The drug resistance is evaluated by detecting the expression level of PINK1 in a sample and combining mitochondrial autophagy activity. The expression level of the PINK1 comprises an mRNA level and / or a protein level. According to the invention, the drug resistance formation process is systematically analyzed from the perspective of quality control of an organelle of mitochondrial autophagy, and through public database analysis and experimental verification, the overall up-regulation of the mitochondrial autophagy pathway in drug-resistant cells is clearly revealed, and the drug-resistant phenotype is promoted by maintaining the mitochondrial steady state, thereby opening up a new direction for understanding the drug-resistant mechanism.

The application discloses application of UFSP2 as a target point in preparation of a prostate cancer treatment product. The application relates to the field of biological medicine, and research finds that UFM1 specific protease 2 (UFSP2) is highly expressed in prostate cancer tissues, and the protein level is higher than that of paracancerous tissues, and is positively correlated with the expression of proliferation related molecules c-Myc and CyclinD1. Function experiments further show that inhibition of UFSP2 expression can significantly inhibit the proliferation, clone formation and migration of prostate cancer cells, and inhibit the growth and metastasis of prostate cancer in vivo; on the contrary, overexpression of UFSP2 can promote the proliferation of prostate cancer cells, indicating that UFSP2 can be used as a prostate cancer treatment target and can be used for screening of anti-prostate cancer drugs. The application provides application of an UFSP2 expression inhibitor and / or a function inhibitor in preparation of a prostate cancer treatment product, and provides a new drug development direction and a targeted intervention strategy for prostate cancer treatment.

The application provides a screening method of human amniotic membrane mesenchymal stem cells (hAMSCs) with bone regeneration promoting potential, and uses the protein level of transmembrane protein 119 (TMEM119) as a functional index of the bone regeneration promoting ability of the hAMSCs, and uses an enzyme-linked immunosorbent assay (ELISA) to detect the TMEM119 protein concentration in a lysis solution prepared from 1×10 7 The application uses the TMEM119 protein concentration not lower than 15000 pg / mL as a screening standard of the hAMSCs with bone regeneration promoting potential, and screens the hAMSCs with significant bone regeneration promoting potential from different batches of hAMSCs, so that the hAMSCs meeting the screening standard of the application have obvious bone formation promoting potential, and the technical problem that the hAMSCs with bone regeneration promoting potential are difficult to be accurately identified and screened in clinical transformation is solved.

The invention discloses application of an Fn1-PPARbeta / delta signal channel related to a cardiac liver disease. The cardiac liver disease model is constructed according to the conditions that the liver development of young individuals is delayed due to heart injury and both adult and young individuals have serious fatty livers. In the model, the Fn1 protein level in the heart and blood is obviously increased compared with the normal level. Based on a zebra fish heart ablation means, after heart ablation injury, the heart specific knock-down Fn1 can lead to reduction of the Fn1 protein level in blood and alleviation of liver development retardation and fat deposition. Through the screening of transcriptomics, the PPARbeta / delta protein in the liver is found to be a potential downstream effect factor of Fn1. The liver specific overexpression PPARbeta / delta protein can significantly relieve abnormal phenotypes such as liver fat deposition caused by heart injury, and after the liver specific knock-down PPARbeta / delta protein, the protection effect of knock-down Fn1 on the liver disappears under the condition of heart injury. Therefore, the Fn1 protein and the PPARbeta / delta protein can be used as targets for preventing and treating the cardiac liver injury, and are used for preparing medicines for improving the cardiac liver injury, so that a new way is provided for treating the cardiac liver disease.

The present invention relates to a composition comprising HAPLN1 as an active ingredient for preventing or treating senile degenerative brain diseases. Specifically, recombinant human HAPLN1 protein (rhHAPLN1) lowers the protein level of p16 in cultured human astrocytes to inhibit cellular senescence caused by the accumulation of beta amyloid peptides, and further inhibits phosphorylation (p-p38 MAPK) of p38 MAPK protein, thereby also having the possibility of inhibiting inflammatory responses associated with the onset of Alzheimer's disease and Parkinson's disease. In addition, the recombinant human HAPLN1 protein (rhHAPLN1) exhibits significant memory and learning improvement effects in in vivo experiments performed using a mouse acute Alzheimer's disease model, and thus can be expected to exhibit preventive and therapeutic effects against Alzheimer's disease that may occur with aging and the like. In addition, the inhibitory effect of the rhHAPLN1 protein on cellular senescence and inflammatory responses of astrocytes can provide a very important clue for establishing prevention and treatment strategies not only for aging itself but also for brain functions, motor behaviors, memory, seizures, dementia, brain tumors, and the like.

The present invention provides oligonucleotides and their use to inhibit viral infections based on lysosome-dependent extracellular secretion pathways. In particular, the oligonucleotides of the invention consist of 10 to 30 modified or unmodified nucleotides. Particularly, the oligonucleotide provided by the invention can effectively reduce the mRNA and protein level of the ADP ribosylation-like factor 8B (ARL8b) gene and promote perinuclear aggregation of lysosome; the compound is expected to be used for inhibiting virus infection based on lysosome-dependent extracellular secretion pathways, such as beta-coronavirus infection.

The present invention relates to a pharmaceutical composition for preventing or treating Parkinson's disease, comprising a 2-(4-(1-hydroxypropane-2-yl)phenyl) isoindoline-1-one compound or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition for preventing or treating Parkinson's disease can increase the protein level of PGC-la in the brain of an individual by successfully passing through the blood-brain barrier (BBB).